These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30513502)

  • 1. Palmar pustular psoriasis associated with teriflunomide treatment.
    Negrotto L; Correale J
    Mult Scler Relat Disord; 2019 Jan; 27():400-402. PubMed ID: 30513502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis.
    Landais A; Alhendi R; Gouverneur A; Teron-Aboud B
    Mult Scler Relat Disord; 2017 Oct; 17():92-94. PubMed ID: 29055483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis.
    Arslan D; Aksakal AB; Erdem Ö; Tuncer MA
    Mult Scler Relat Disord; 2020 Aug; 43():102157. PubMed ID: 32446168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
    Gerschenfeld G; Servy A; Valeyrie-Allanore L; de Prost N; Cecchini J
    Mult Scler; 2015 Oct; 21(11):1476-7. PubMed ID: 26199352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
    Camara-Lemarroy CR; Castilló J; Sastre-Garriga J; Tintore M; Montalban X
    Mult Scler; 2018 Sep; 24(10):1383-1385. PubMed ID: 29473796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Nail loss after teriflunomide treatment: A new potential adverse event".
    Mancinelli L; Amerio P; di Ioia M; Di Tommaso V; De Luca G; Onofrj M; Lugaresi A
    Mult Scler Relat Disord; 2017 Nov; 18():170-172. PubMed ID: 29141803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
    Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP
    Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
    Yamout BI; Said M; Hannoun S; Zeineddine M; Massouh J; Khoury SJ
    J Neurol Sci; 2017 Sep; 380():79-81. PubMed ID: 28870594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digestive side-effects with teriflunomide: Thoughts on lactose.
    Lebrun C; Bertagna M; Bresch S; Cohen M
    Rev Neurol (Paris); 2018 Dec; 174(10):722-725. PubMed ID: 30409479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary embolism in patients with multiple sclerosis treated with teriflunomide: A series of three cases.
    Krajnc N; Brecl Jakob G; Gomezelj S; Šega Jazbec S
    Clin Neurol Neurosurg; 2021 Jul; 206():106685. PubMed ID: 34020325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE
    Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ▼Teriflunomide for multiple sclerosis.
    Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Brette S; Robinson M; Gold R;
    Mult Scler Relat Disord; 2017 Oct; 17():107-115. PubMed ID: 29055438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
    Miller AE
    Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.
    Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT
    Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
    Freedman MS; Wolinsky JS; Wamil B; Confavreux C; Comi G; Kappos L; Olsson TP; Miller A; Benzerdjeb H; Li H; Simonson C; O'Connor PW;
    Neurology; 2012 Jun; 78(23):1877-85. PubMed ID: 22622860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
    Papadopoulou A; Kappos L; Sprenger T
    Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.
    Chan A; de Seze J; Comabella M
    CNS Drugs; 2016 Jan; 30(1):41-51. PubMed ID: 26758290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.